Table 3 Objective response rates for over all population and subgroups of patients
N | Overall response rate (%) | Clinical benefit rate (%) | Median PFS (95%CI), months | |
|---|---|---|---|---|
Overall | 32 | 43.8 | 56.3 | 8.3 (7.1–9.4) |
Hormone receptor status | ||||
HR(−) | 12 | 33.3 | 41.7 | 5.5 (0–11.5) |
HR(+) | 20 | 50 | 65 | 8.8 (6.46–11.0) |
No. of prior chemotherapy | ||||
0 | 22 | 50 | 54.5 | 8.8 (7.4–10.1) |
1 | 10 | 30 | 70 | 8.3 (3.7–12.8) |
Metastatic site | ||||
Visceral | 23 | 43.5 | 60.9 | 8.3 (7.2–9.3) |
Non-visceral | 9 | 44.4 | 44.4 | 9.0 (4.2–13.8) |
Dose reduction during treatment | ||||
No reduction | 18 | 33.3 | 50 | 8.8 (3.9–13.6) |
Reduction | 14 | 57.1 | 64.3 | 8.3 (7.8–8.7) |
Hormone receptor status | ||||
Triple negative | 11 | 36.4 | 36.4 | 5.5 (1.3–9.7) |
Other | 21 | 47.6 | 71.4 | 8.8 (7.0–10.5) |